Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Dynamic myelin regulation as a novel form of neural plasticity . Yuliana
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 53, No 1 (2021)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (275.696 KB) | DOI: 10.19106/JMedSci005301202107

Abstract

Dynamic changes in myelin could optimize information transmission in neuralcircuits and enhance conduction velocity. This review aimed to provide anunderstanding of how dynamic myelin plasticity is important in neuronalactivity and how astrocytes have an important role that is not equal in theperipheral nervous system. Myelin is dynamically regulated by neuronalactivity. It takes part continuously in nervous system plasticity duringdevelopment. Newly differentiating oligodendrocytes can create a new myelinsheath. Mature myelin sheaths can grow again in adults. Oligodendrocytesinteract with astrocytes in the central nervous system through gap junctions.Astrocytes have an important role as synaptic network integrators; therefore,decreasing astrocyte numbers will cause a loss of presynaptic plasticity. Theconcept considers plasticity as a mechanism that depends on myelination.Higher brain functions and myelination interplay in the hippocampus andprefrontal cortex. The mechanism and function of these changes remainpoorly understood. Genetic, neural activity, environment, and axonal activitymight play important roles. Dynamic myelin regulation reveals a new form ofneural plasticity. Myelination is similar to synapse formation and plasticity. Itenables plasticity in the central nervous system and helps improve the learningprocess.
Controversy of angiotensin receptor blockers (ARBs) and angiotensin converting enzymeinhibitors (ACEIs) prescription for hypertension patients in coronavirus disease 2019 (COVID-19) pandemic Yuliana Yuliana
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 52, No 3 (2020): Special Issue: COVID-19
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (358.251 KB) | DOI: 10.19106/JMedSciSI005203202006

Abstract

Coronavirus disease 2019 (COVID-19) pandemic has made all the world in a mess. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 infects human cells through angiotensin-converting enzyme 2 receptors (ACE receptors). Angiotensin-converting enzyme 2 (ACE) is upregulated in diabetes and cardiovascular diseases including hypertension. Hypertension patients commonly consume angiotensin receptor blockers (ARBs) and/or angiotensin-converting enzyme inhibitors (ACEIs) which could increase ACE receptors. It was suspected that the ARBs or ACEIs administration may worsen the clinical outcome for the hypertension patients with COVID-19. However, no clinical trial had significantly revealed how appropriate management and prescription of ARBs and ACEIs for the hypertension patients with COVID-19. The use of ARBs and ACEIs for these patients is still controversy. Studies concerning the side effect of single or combination use of ARBs and ACEIs in the hypertension patients with COVID-19 as well as specific morbidity and mortality are needed. This review was aimed to provide understanding concerning the appropriate management and prescription of ARBs and ACEIs for hypertension patients with COVID-19.